{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:50:40Z","timestamp":1767340240290},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1504,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1111\/j.1365-2133.2011.10402.x","type":"journal-article","created":{"date-parts":[[2011,5,11]],"date-time":"2011-05-11T14:19:15Z","timestamp":1305123555000},"page":"411-414","source":"Crossref","is-referenced-by-count":60,"title":["Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis"],"prefix":"10.1093","volume":"165","author":[{"given":"V.","family":"Ramesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.K.","family":"Katara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Salotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,7,20]]},"reference":[{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1473-3099(03)00517-6","article-title":"Post kala azar dermal leishmaniasis","volume":"3","author":"Zijlstra","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/505079","article-title":"High incidence of antimony refractoriness in Indian Kala azar is contributed by anthroponotic transmission via post kala azar dermal leishmaniasis","volume":"194","author":"Singh","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-94-007-0277-6_11","volume-title":"Kala Azar in South Asia - Current Status and Challenges Ahead","author":"Desjeaux","year":"2011"},{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"e101002","DOI":"10.1371\/journal.pone.0010107","article-title":"Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 correlates with parasite load in visceral leishmaniasis","volume":"5","author":"Verma","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1046\/j.1365-2133.2001.04434.x","article-title":"A simple and sensitive test for field diagnosis of post kala-azar dermal leishmaniasis","volume":"145","author":"Salotra","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(98)04367-0","article-title":"Trial of oral miltefosine in visceral leishmaniasis","volume":"352","author":"Sundar","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.trstmh.2005.09.015","article-title":"Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine","volume":"100","author":"Sundar","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB8|cit8","first-page":"103","article-title":"Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis","volume":"33","author":"Ramesh","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drup.2004.07.002","article-title":"Leishmaniasis: drugs in the clinic, resistance and new developments","volume":"7","author":"Ouellette","year":"2004","journal-title":"Drug Resist Updat"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2133.2011.10402.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.trstmh.2006.02.010","article-title":"Development of miltefosine as an oral treatment for leishmaniasis","volume":"100","author":"Sindermann","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-4632.2010.04326.x","article-title":"Oral miltefosine in post-kala-azar dermal leishmaniasis","volume":"49","author":"Khandpur","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.trstmh.2008.05.015","article-title":"Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis","volume":"102","author":"Ansari","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","article-title":"Phase 4 trial of miltefosine for the treatment of visceral leishmaniasis","volume":"196","author":"Bhattacharya","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/BF02535544","article-title":"Metabolism of ether phospholipids and analogs in neoplastic cells","volume":"22","author":"Fleer","year":"1987","journal-title":"Lipids"},{"key":"10.1111\/j.1365-2133.2011.10402.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1517\/17425255.4.9.1209","article-title":"Treatment of leishmaniasis with miltefosine: 2008 status","volume":"4","author":"Berman","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2011.10402.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2011.10402.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:52:20Z","timestamp":1676382740000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/165\/2\/411\/6644225"}},"subtitle":["Miltefosine in PKDL"],"short-title":[],"issued":{"date-parts":[[2011,7,20]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10402.x","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7,20]]}}}